|
humans |
37 |
|
male |
35 |
|
female |
34 |
|
medical sciences |
34 |
|
aged |
33 |
|
middle aged |
32 |
|
adult |
29 |
|
diabetes |
28 |
|
atrial fibrillation |
22 |
|
cardiovascular disease |
21 |
|
obesity |
20 |
|
risk factors |
20 |
|
coronary artery disease |
19 |
|
diabetes mellitus |
19 |
|
chemicals and cas registry numbers |
18 |
|
blood pressure |
17 |
|
lipocalin-2 |
17 |
|
mortality |
17 |
|
stroke |
17 |
|
cancer |
16 |
|
chinese |
16 |
|
hypertension |
16 |
|
prevalence |
16 |
|
body mass index |
15 |
|
type 2 diabetes |
15 |
|
type 2 diabetes mellitus |
15 |
|
case-control studies |
14 |
|
cross-sectional studies |
14 |
|
epidemiology |
14 |
|
myocardial infarction |
14 |
|
china - epidemiology |
13 |
|
genotype |
13 |
|
metabolic syndrome |
13 |
|
multivariate analysis |
13 |
|
aged, 80 and over |
12 |
|
cardiovascular diseases |
12 |
|
hong kong |
12 |
|
hong kong - epidemiology |
12 |
|
regression analysis |
12 |
|
adrenomedullin |
11 |
|
animals |
11 |
|
asian continental ancestry group - genetics |
11 |
|
blood glucose - analysis |
11 |
|
carotid intima-media thickness |
11 |
|
fatty liver disease |
11 |
|
inflammation |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
predictive value of tests |
11 |
|
questionnaires |
11 |
|
secondary prevention |
11 |
|
25-hydroxyvitamin d |
10 |
|
adipocyte |
10 |
|
age factors |
10 |
|
b-type natriuretic peptide |
10 |
|
biomarker |
10 |
|
c-reactive protein |
10 |
|
cardiac troponin |
10 |
|
covid-19 |
10 |
|
diet |
10 |
|
fibroblast growth factor |
10 |
|
gastrointestinal haemorrhage |
10 |
|
hypertension - blood - genetics |
10 |
|
insulin resistance |
10 |
|
mendelian randomization |
10 |
|
odds ratio |
10 |
|
prospective studies |
10 |
|
risk factor |
10 |
|
risk prediction |
10 |
|
time in therapeutic range |
10 |
|
united states - epidemiology |
10 |
|
vitamin d |
10 |
|
adiponectin |
9 |
|
asian-specific |
9 |
|
biological markers - blood |
9 |
|
cholesterol |
9 |
|
cohort studies |
9 |
|
exercise |
9 |
|
exome-chip association analysis |
9 |
|
fatty acid-binding proteins - blood |
9 |
|
gene |
9 |
|
genetic predisposition to disease |
9 |
|
linkage disequilibrium |
9 |
|
meta-analysis |
9 |
|
pax4 |
9 |
|
polymorphism |
9 |
|
polymorphism, single nucleotide - genetics |
9 |
|
sex factors |
9 |
|
adiponectin - blood - genetics |
8 |
|
association |
8 |
|
blood pressure - genetics |
8 |
|
calcium |
8 |
|
cells, cultured |
8 |
|
dyslipidemia |
8 |
|
follow-up studies |
8 |
|
haplotype |
8 |
|
haplotypes |
8 |
|
hyperglycaemia |
8 |
|
metabolism |
8 |
|
polymorphism, genetic |
8 |
|
polymorphism, single nucleotide |
8 |
|
single-nucleotide polymorphism |
8 |
|
trs 2°p |
8 |
|
adipocytes - metabolism - pathology |
7 |
|
adiponectin - blood |
7 |
|
arterial stiffness |
7 |
|
brain ischemia - blood - diagnosis - mortality |
7 |
|
cardiovascular mortality |
7 |
|
cholesterol - blood |
7 |
|
circulating endothelial progenitor cells |
7 |
|
confounding factors (epidemiology) |
7 |
|
endocrinology |
7 |
|
endothelial function |
7 |
|
gene frequency |
7 |
|
genetic predisposition to disease - genetics |
7 |
|
heart failure |
7 |
|
impaired glucose tolerance |
7 |
|
lipids |
7 |
|
metabolic syndrome x - genetics |
7 |
|
nutrition surveys |
7 |
|
pharmacoepidemiology |
7 |
|
pleiotropic effects |
7 |
|
single nucleotide polymorphism |
7 |
|
statin therapy |
7 |
|
stroke - blood - diagnosis - mortality |
7 |
|
adiponectin - genetics |
6 |
|
adipose tissue - chemistry |
6 |
|
adiposity - physiology |
6 |
|
all-cause mortality |
6 |
|
amino acid substitution |
6 |
|
angiotensin receptor blockers |
6 |
|
angiotensinconverting enzyme inhibitors |
6 |
|
ankle brachial index |
6 |
|
anti-coagulant |
6 |
|
asian continental ancestry group |
6 |
|
asian continental ancestry group - statistics and numerical data |
6 |
|
biological markers |
6 |
|
biological markers - blood - metabolism |
6 |
|
blood flow velocity |
6 |
|
blood glucose - metabolism |
6 |
|
blood pressure - physiology |
6 |
|
bone metabolism |
6 |
|
brachial artery - physiopathology |
6 |
|
cardiovascular diseases - etiology |
6 |
|
cell adhesion molecules - blood |
6 |
|
clarithromycin - adverse effects - contraindications |
6 |
|
cohort profile // chinese |
6 |
|
colchicine - adverse effects - contraindications |
6 |
|
covid-19 incidence |
6 |
|
crisps |
6 |
|
deficiency diseases - complications - physiopathology |
6 |
|
diabetes mellitus, type 2 - diagnosis - ethnology - genetics |
6 |
|
diet records |
6 |
|
dipeptidyl peptidase-4 inhibitors |
6 |
|
doac |
6 |
|
drug interactions |
6 |
|
dysglycemia |
6 |
|
energy intake |
6 |
|
epidemiological studies |
6 |
|
fibrinogen |
6 |
|
fibrinogen - genetics - metabolism |
6 |
|
gamma-glutamyltransferase - blood - metabolism |
6 |
|
genetic variation |
6 |
|
ggt |
6 |
|
glucose intolerance - blood - genetics |
6 |
|
glycosylated hemoglobin a |
6 |
|
homeostasis |
6 |
|
hong kong - epidemiology - ethnology |
6 |
|
hyperglycemia - complications - epidemiology |
6 |
|
hypertension - blood - enzymology - epidemiology |
6 |
|
hypertension - blood - epidemiology |
6 |
|
hypertension - blood - epidemiology - genetics |
6 |
|
hypertension - blood - ethnology - genetics - physiopathology |
6 |
|
hypertension - complications - epidemiology |
6 |
|
hypertension - epidemiology |
6 |
|
hypertriglyceridemia - epidemiology |
6 |
|
igt |
6 |
|
insulin |
6 |
|
insulin resistance - genetics |
6 |
|
insulin resistance - physiology |
6 |
|
intensive care unit |
6 |
|
interleukin-6 |
6 |
|
interleukin-6 - blood - genetics |
6 |
|
intubation |
6 |
|
kidney |
6 |
|
kidney failure - complications |
6 |
|
likelihood functions |
6 |
|
liver |
6 |
|
liver - pathology |
6 |
|
liver function test |
6 |
|
metabolic syndrome x - blood - epidemiology - etiology |
6 |
|
metabolic syndrome x - complications - epidemiology - mortality |
6 |
|
mice |
6 |
|
mice, inbred c57bl |
6 |
|
mineral metabolism |
6 |
|
models, biological |
6 |
|
nutrition |
6 |
|
nutrition assessment |
6 |
|
obesity - blood - complications |
6 |
|
obesity - epidemiology |
6 |
|
obesity - genetics |
6 |
|
obesity - genetics - metabolism |
6 |
|
parathyroid hormone |
6 |
|
pharmacokinetics |
6 |
|
pharmacy and pharmacology environmental studies |
6 |
|
potassium channels, inwardly rectifying - genetics |
6 |
|
prediabetic state - diagnosis - ethnology - genetics |
6 |
|
prediction |
6 |
|
proportional hazards models |
6 |
|
receptors, cell surface - blood |
6 |
|
selenium - administration & dosage - deficiency |
6 |
|
selenium deficiency |
6 |
|
sex distribution |
6 |
|
single nucleotide |
6 |
|
single nucleotide polymorphisms |
6 |
|
sodium |
6 |
|
sodium-glucose co-transporter |
6 |
|
sodium-glucose cotransporter-2 inhibitors |
6 |
|
toxicology and environmental safety |
6 |
|
trace elements - deficiency |
6 |
|
triglycerides - blood |
6 |
|
vascular diseases - etiology - mortality |
6 |
|
vascular diseases - etiology - physiopathology |
6 |
|
vascular function |
6 |
|
γ-glutamyl transaminase |
6 |
|
adverse cardiovascular outcomes |
5 |
|
adverse drug reaction |
5 |
|
age distribution |
5 |
|
agranulocytosis |
5 |
|
alleles |
5 |
|
alzheimer's disease |
5 |
|
anti-oxidant |
5 |
|
apolipoprotein e4 - genetics |
5 |
|
aspirin |
5 |
|
atherosclerosis - epidemiology - metabolism - prevention & control |
5 |
|
avascular necrosis |
5 |
|
blood pressure - drug effects |
5 |
|
blood sampling |
5 |
|
bone mineral density |
5 |
|
bone turnover markers |
5 |
|
buddy |
5 |
|
cardio-renal metabolic syndrome |
5 |
|
cardiovascular diseases - blood - epidemiology |
5 |
|
cardiovascular risk |
5 |
|
cell adhesion molecules |
5 |
|
cell adhesion molecules - genetics |
5 |
|
china |
5 |
|
cholesterol, hdl - blood |
5 |
|
clinical outcomes |
5 |
|
clopidogrel |
5 |
|
depression |
5 |
|
diabetes mellitus - blood - drug therapy - epidemiology |
5 |
|
diabetes mellitus, type 2 - pathology - physiopathology |
5 |
|
dietary fats |
5 |
|
dietary fiber - therapeutic use |
5 |
|
disease association |
5 |
|
dose-response relationship, drug |
5 |
|
drug therapy, combination |
5 |
|
elbasvir |
5 |
|
elderly |
5 |
|
electronic frailty index |
5 |
|
endothelial cells - pathology |
5 |
|
endothelium, vascular - physiopathology |
5 |
|
exercise therapy |
5 |
|
f11 receptor |
5 |
|
family history |
5 |
|
fasting - blood |
5 |
|
ferritins - blood |
5 |
|
fibroblast growth factor 21 |
5 |
|
fish |
5 |
|
fish oils |
5 |
|
follow-up |
5 |
|
food habits |
5 |
|
fruit |
5 |
|
fruits |
5 |
|
gene polymorphism |
5 |
|
general population |
5 |
|
genetics |
5 |
|
glucocorticoids |
5 |
|
glucose intolerance - blood - etiology |
5 |
|
glucose tolerance test |
5 |
|
glycaemia |
5 |
|
grazoprevir |
5 |
|
guidelines as topic |
5 |
|
health utility |
5 |
|
health-related quality of life |
5 |
|
hemoglobin a, glycosylated - metabolism |
5 |
|
hong kong chinese population |
5 |
|
hypertension - ethnology - genetics |
5 |
|
hypertension - genetics - physiopathology |
5 |
|
hypoglycemic agents - therapeutic use |
5 |
|
insulin - blood |
5 |
|
lean mass |
5 |
|
legumes |
5 |
|
meat |
5 |
|
mental health |
5 |
|
myocarditis |
5 |
|
myopericarditis |
5 |
|
non-communicable disease |
5 |
|
non‐invasive |
5 |
|
non–vitamin k antagonist oral anticoagulants |
5 |
|
nuclear proteins - genetics |
5 |
|
obesity - ethnology - genetics |
5 |
|
osteoporosis |
5 |
|
pedometer |
5 |
|
pericarditis |
5 |
|
physical activity |
5 |
|
physiology |
5 |
|
polyamination |
5 |
|
population norm |
5 |
|
preventive medicine |
5 |
|
primary care |
5 |
|
prognosis |
5 |
|
psychiatric status rating scales |
5 |
|
public health |
5 |
|
pulmonary hypertension |
5 |
|
quality of life |
5 |
|
random survival forest (rsf) |
5 |
|
rats |
5 |
|
receptors, cell surface - genetics |
5 |
|
reference values |
5 |
|
renal complications |
5 |
|
respiratory diseases |
5 |
|
retrospective studies |
5 |
|
safety |
5 |
|
salt |
5 |
|
sarcopenia |
5 |
|
sars |
5 |
|
score |
5 |
|
self-perceived |
5 |
|
sex characteristics |
5 |
|
statins |
5 |
|
stem cells - pathology |
5 |
|
trials |
5 |
|
unintentional injury |
5 |
|
urinary sodium excretion |
5 |
|
vaccine |
5 |
|
vascular diseases - epidemiology - metabolism - prevention & control |
5 |
|
vegetables |
5 |
|
vitamin a |
5 |
|
vitamin c |
5 |
|
vitamin d deficiency - pathology |
5 |
|
vitamin e |
5 |
|
vitamins - therapeutic use |
5 |
|
water-electrolyte balance - physiology |
5 |
|
young adult |
5 |
|
administration, oral |
4 |
|
adolescent |
4 |
|
aging - blood |
4 |
|
albuminuria - physiopathology |
4 |
|
alkaline phosphatase |
4 |
|
alkaline phosphatase - blood |
4 |
|
alpha-thalassemia - complications - physiopathology |
4 |
|
amlodipine |
4 |
|
amlodipine - pharmacology - therapeutic use |
4 |
|
anticholesteremic agents - pharmacology - therapeutic use |
4 |
|
antihypertensive agent |
4 |
|
antihypertensive agents - pharmacology - therapeutic use |
4 |
|
anxiety - psychology |
4 |
|
apolipoproteins a - genetics |
4 |
|
atorvastatin |
4 |
|
beta-trace protein |
4 |
|
bia |
4 |
|
blood lead level |
4 |
|
blood pressure variability |
4 |
|
body weight |
4 |
|
bone health |
4 |
|
brachial artery - physiology - ultrasonography |
4 |
|
breathing exercises |
4 |
|
c-reactive protein - biosynthesis |
4 |
|
cardiovascular diseases - blood - diagnosis - ethnology |
4 |
|
cardiovascular diseases - blood - epidemiology - etiology - physiopathology |
4 |
|
cardiovascular diseases - epidemiology |
4 |
|
cardiovascular diseases - epidemiology - ethnology |
4 |
|
chloramphenicol succinate |
4 |
|
chromatography, high pressure liquid |
4 |
|
circadian rhythm |
4 |
|
clinical trials |
4 |
|
coronary artery disease - blood - complications - drug therapy |
4 |
|
ct |
4 |
|
depression - psychology |
4 |
|
diabetes mellitus - epidemiology |
4 |
|
diabetes mellitus, type 2 - blood - pathology |
4 |
|
diastole |
4 |
|
dietary patterns |
4 |
|
drug combinations |
4 |
|
dxa |
4 |
|
echocardiography, doppler, pulsed |
4 |
|
endothelial progenitor cells |
4 |
|
endothelium, vascular - cytology - metabolism |
4 |
|
endothelium, vascular - drug effects - physiology |
4 |
|
ferritin |
4 |
|
gene deletion |
4 |
|
gout |
4 |
|
haemoglobin h disease |
4 |
|
health care costs |
4 |
|
health knowledge, attitudes, practice |
4 |
|
health status |
4 |
|
heart rate |
4 |
|
heptanoic acids - pharmacology - therapeutic use |
4 |
|
heterozygote |
4 |
|
hip fracture |
4 |
|
hypercholesterolemia - blood - ethnology |
4 |
|
hypertension - blood - complications - drug therapy |
4 |
|
hypertension - blood - complications - epidemiology - etiology - physiopathology |
4 |
|
hypertension - genetics |
4 |
|
hypertension - physiopathology - psychology - therapy - urine |
4 |
|
iron |
4 |
|
iron - metabolism |
4 |
|
iron chelating agents - adverse effects - therapeutic use |
4 |
|
iron overload |
4 |
|
iron overload - drug therapy - etiology - physiopathology - ultrasonography |
4 |
|
life style |
4 |
|
linear models |
4 |
|
liver - metabolism |
4 |
|
longitudinal studies |
4 |
|
magnetic resonance imaging - methods |
4 |
|
mediterranean diet |
4 |
|
metabolic syndrome x - blood - complications - epidemiology - physiopathology |
4 |
|
metabolic syndrome x - blood - diagnosis |
4 |
|
metabolic syndrome x - complications - epidemiology |
4 |
|
metabolomics |
4 |
|
nafld |
4 |
|
nafld liver fat score |
4 |
|
nhanes |
4 |
|
nhanes iii |
4 |
|
niacin |
4 |
|
oral antidiabetic agent |
4 |
|
oral chelator |
4 |
|
pigment epithelium derived factor |
4 |
|
polymerase chain reaction |
4 |
|
pre-diabetes |
4 |
|
primary prevention |
4 |
|
proton pump inhibition |
4 |
|
pyridones - adverse effects - therapeutic use |
4 |
|
pyrroles - pharmacology - therapeutic use |
4 |
|
qigong |
4 |
|
radioimmunoassay |
4 |
|
renin - blood |
4 |
|
risk assessment |
4 |
|
serum calcium |
4 |
|
serum metabolites |
4 |
|
severity of illness index |
4 |
|
stem cells - metabolism |
4 |
|
systematic review |
4 |
|
threshold level |
4 |
|
transferrin saturation |
4 |
|
urotensin ii |
4 |
|
validation studies |
4 |
|
ventricular function, left |
4 |
|
vertebral fracture |
4 |
|
waist circumference |
4 |
|
abbreviations |
3 |
|
abca1 |
3 |
|
adrenomedullin - blood |
3 |
|
age of onset |
3 |
|
aging |
3 |
|
allergic rhinitis |
3 |
|
alpha-thalassemia - blood - classification - genetics - physiopathology |
3 |
|
alzheimer disease - blood |
3 |
|
alzheimer disease - blood - diagnosis - ethnology |
3 |
|
alzheimer disease - diagnosis - epidemiology - genetics |
3 |
|
alzheimer disease - ethnology - genetics |
3 |
|
alzheimer disease - genetics - physiopathology |
3 |
|
analysis of variance |
3 |
|
antidiabetic drugs |
3 |
|
antihypertensive agents - therapeutic use |
3 |
|
apolipoproteins |
3 |
|
arrhythmia |
3 |
|
asian continental ancestry group - ethnology |
3 |
|
atherosclerosis |
3 |
|
atp-binding cassette transporters - genetics |
3 |
|
beta-2 microglobulin |
3 |
|
biological availability |
3 |
|
bleeding |
3 |
|
body composition |
3 |
|
body weight - physiology |
3 |
|
bone marrow - drug effects - metabolism |
3 |
|
bone marrow - drug effects - physiology |
3 |
|
cardiovascular diseases - blood - ethnology - genetics |
3 |
|
cardiovascular risk factors |
3 |
|
carotid plaque |
3 |
|
case-control |
3 |
|
cell line |
3 |
|
chi-square distribution |
3 |
|
chloramphenicol |
3 |
|
chloramphenicol - analogs & derivatives - analysis - pharmacology - toxicity |
3 |
|
chloramphenicol - analogs and derivatives - metabolism |
3 |
|
cholesterol metabolism |
3 |
|
cholesterol, hdl/blood |
3 |
|
chromosomes, human, 16-18 |
3 |
|
chronic kidney disease |
3 |
|
cognition - physiology |
3 |
|
cognition disorders - blood |
3 |
|
cognition disorders - genetics - physiopathology |
3 |
|
community health centers - trends |
3 |
|
control |
3 |
|
coronary heart disease |
3 |
|
cox regression |
3 |
|
cyclic amp - metabolism |
3 |
|
cyp46a 1 |
3 |
|
delayed-action preparations |
3 |
|
diabetes incidence |
3 |
|
diabetes mellitus - blood - diet therapy - drug therapy - epidemiology - ethnology |
3 |
|
diabetes mellitus - epidemiology - ethnology - therapy |
3 |
|
diet therapy |
3 |
|
dietary supplements |
3 |
|
disease progression |
3 |
|
double-blind method |
3 |
|
drug acquisition costs |
3 |
|
drug-eluting stent |
3 |
|
dual antiplatelet therapy |
3 |
|
dyslipidemias - drug therapy - physiopathology |
3 |
|
endotoxemia - metabolism |
3 |
|
endotoxin |
3 |
|
erratum |
3 |
|
error |
3 |
|
fasting glucose |
3 |
|
gait |
3 |
|
gait speed |
3 |
|
gender difference |
3 |
|
geriatric assessment |
3 |
|
haemoglobin a1c |
3 |
|
health surveys |
3 |
|
hemorrhagic stroke/transformation |
3 |
|
homozygote |
3 |
|
human bone marrow |
3 |
|
human bone marrow and liver |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects - pharmacology - therapeutic use |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use |
3 |
|
hyperglycemia - drug therapy |
3 |
|
hypertension - drug therapy |
3 |
|
hypertension, pulmonary - blood - etiology |
3 |
|
hypertriglyceridaemia |
3 |
|
hypoglycemic agents - administration and dosage - therapeutic use |
3 |
|
hypolipidemic agents - adverse effects - pharmacology - therapeutic use |
3 |
|
indoles - adverse effects - pharmacology - therapeutic use |
3 |
|
insulin - administration and dosage - therapeutic use |
3 |
|
intracranial occlusive disease |
3 |
|
introns - genetics |
3 |
|
kidney - drug effects - physiology |
3 |
|
laropiprant |
3 |
|
ldl |
3 |
|
liver - drug effects - physiology |
3 |
|
losartan |
3 |
|
lung - chemistry |
3 |
|
lung diseases, interstitial - blood - etiology |
3 |
|
medication errors |
3 |
|
men |
3 |
|
metabolic syndrome x - diet therapy - drug therapy - epidemiology - ethnology |
3 |
|
metabolic syndrome x - epidemiology |
3 |
|
microsatellite repeats |
3 |
|
mild cognitive impairment |
3 |
|
mitochondria - drug effects - physiology |
3 |
|
mutagenesis, site-directed |
3 |
|
mutation, missense |
3 |
|
natriuretic peptide, brain |
3 |
|
nerve tissue proteins - blood |
3 |
|
network meta-analysis |
3 |
|
neuropsychological tests |
3 |
|
niacin - adverse effects - pharmacology - therapeutic use |
3 |
|
nnt |
3 |
|
non-vitamin k oral anticoagulants |
3 |
|
oxidation-reduction |
3 |
|
oxidative stress |
3 |
|
pedigree |
3 |
|
peptides - analysis - blood |
3 |
|
peptides - blood |
3 |
|
peripheral arterial disease |
3 |
|
phytosterol |
3 |
|
plant sterol |
3 |
|
polymorphism, genetic - genetics |
3 |
|
polymorphism, restriction fragment length |
3 |
|
prescribing |
3 |
|
protein synthesis inhibitors - analysis |
3 |
|
quantitative trait, heritable |
3 |
|
randomized controlled trials as topic |
3 |
|
rat liver and kidney mitochondria |
3 |
|
rats, sprague-dawley |
3 |
|
raynaud disease - blood - etiology |
3 |
|
receptor, melanocortin, type 4 - genetics - metabolism |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
scleroderma, systemic - blood - complications - physiopathology |
3 |
|
sensitivity and specificity |
3 |
|
sglt2 inhibitors |
3 |
|
signal transduction |
3 |
|
simvastatin |
3 |
|
simvastatin - adverse effects - pharmacology - therapeutic use |
3 |
|
single nucleotide polymorphisms (snp) |
3 |
|
steroid hydroxylases - genetics |
3 |
|
stroke/systemic embolism |
3 |
|
succinate dehydrogenase |
3 |
|
succinate dehydrogenase - antagonists & inhibitors - pharmacology |
3 |
|
testosterone |
3 |
|
testosterone - blood |
3 |
|
time factors |
3 |
|
tissue distribution |
3 |
|
total cholesterol |
3 |
|
transfection - methods |
3 |
|
treatment outcome |
3 |
|
triglycerides |
3 |
|
united states |
3 |
|
urate-lowering therapy |
3 |
|
urotensins - genetics - metabolism |
3 |
|
vascular disease vitamin d |
3 |
|
vitamin d - analogs and derivatives - blood - therapeutic use |
3 |
|
vitamin k |
3 |
|
vitamins - blood - therapeutic use |
3 |
|
waist circumference - physiology |
3 |
|
warfarin |
3 |
|
25‐hydroxyvitamin d |
2 |
|
adrenal |
2 |
|
adrenal glands - drug effects - metabolism |
2 |
|
adrenomedullin - analysis - metabolism - therapeutic use |
2 |
|
aerospace medicine |
2 |
|
african continental ancestry group - statistics & numerical data |
2 |
|
aging - genetics - metabolism |
2 |
|
allergic sensitization |
2 |
|
allopurinol |
2 |
|
amiodarone |
2 |
|
amiodarone - therapeutic use |
2 |
|
analgesia |
2 |
|
anesthesia |
2 |
|
angioplasty, balloon, coronary - economics - rehabilitation |
2 |
|
angiotensin-converting enzyme |
2 |
|
angiotensinogen |
2 |
|
anti-arrhythmia agents - therapeutic use |
2 |
|
anti-inflammatory agents - pharmacology |
2 |
|
antibodies, antinuclear - blood |
2 |
|
anticholesteremic agents - administration & dosage - adverse effects |
2 |
|
antihypertensive agents |
2 |
|
antihypertensive drugs |
2 |
|
antihypertensive therapy |
2 |
|
antineoplastic agents - economics - pharmacokinetics - therapeutic use |
2 |
|
antiobesity drugs |
2 |
|
aorta, thoracic - chemistry |
2 |
|
asians |
2 |
|
atria |
2 |
|
atrial fibrillation - drug therapy - physiopathology |
2 |
|
atrial natriuretic factor - genetics |
2 |
|
atrial natriuretic peptide |
2 |
|
awareness |
2 |
|
beers criteria |
2 |
|
behavior therapy |
2 |
|
beta-2-microglobulin |
2 |
|
biobank |
2 |
|
biological markers - analysis |
2 |
|
biological products - economics/pharmacokinetics - therapeutic use |
2 |
|
biological specimen banks |
2 |
|
blood coagulation |
2 |
|
blood pressure monitoring |
2 |
|
body build |
2 |
|
body fat |
2 |
|
body mass |
2 |
|
body weight loss |
2 |
|
bogalusa |
2 |
|
bogalusa heart study |
2 |
|
brain hemorrhage |
2 |
|
bridging |
2 |
|
c-reactive protein - metabolism |
2 |
|
calcium channel blockers - therapeutic use |
2 |
|
cardiovascular disease prevention |
2 |
|
cardiovascular diseases - diagnosis - epidemiology - ethnology - genetics |
2 |
|
cardiovascular diseases - prevention & control |
2 |
|
cardiovascular system |
2 |
|
cardiovascular system - chemistry - drug effects |
2 |
|
carotid arteries - ultrasonography |
2 |
|
carotid artery |
2 |
|
carotid artery diseases - ethnology - genetics - ultrasonography |
2 |
|
carotid artery intima-media thickness |
2 |
|
causation |
2 |
|
cerebral artery stenoses |
2 |
|
cetilistat |
2 |
|
cholesterol blood level |
2 |
|
cholesterol, ldl - blood |
2 |
|
cluster‐randomized controlled trial |
2 |
|
cohort |
2 |
|
comorbidity |
2 |
|
control nonlinearities |
2 |
|
cooperative behavior |
2 |
|
cost-benefit analysis |
2 |
|
cost-effectiveness |
2 |
|
costs |
2 |
|
costs and cost analysis |
2 |
|
culture media, conditioned - pharmacology |
2 |
|
cystatin c |
2 |
|
cytokines |
2 |
|
cytokines - biosynthesis - metabolism |
2 |
|
death |
2 |
|
deoxyribonuclease hpaii - genetics |
2 |
|
diabetes mellitus, type 2 - mortality - prevention & control |
2 |
|
diet - statistics and numerical data - trends |
2 |
|
diet surveys |
2 |
|
digoxin |
2 |
|
digoxin - therapeutic use |
2 |
|
dna - analysis |
2 |
|
dna primers - chemistry |
2 |
|
drug administration schedule |
2 |
|
drug costs |
2 |
|
drug related hospital admission |
2 |
|
drug safety |
2 |
|
dyslipidemias - drug therapy - epidemiology |
2 |
|
echocardiography |
2 |
|
editorials |
2 |
|
electric coils |
2 |
|
electric motors |
2 |
|
electrocardiography, ambulatory |
2 |
|
electrophoresis, polyacrylamide gel |
2 |
|
enalapril - therapeutic use |
2 |
|
epidemiologic research design |
2 |
|
escherichia coli - metabolism |
2 |
|
ethnic group |
2 |
|
exercise test |
2 |
|
exercise therapy - economics |
2 |
|
factor v |
2 |
|
factor v - genetics - metabolism |
2 |
|
family practice |
2 |
|
febuxostat |
2 |
|
fenfluramine |
2 |
|
fgf21 |
2 |
|
fibrinogen - genetics |
2 |
|
gene expression |
2 |
|
gene expression - physiology |
2 |
|
gene expression regulation |
2 |
|
genetic markers |
2 |
|
genetics, population |
2 |
|
glucagon-like peptide-1 receptor agonists |
2 |
|
glucocorticoids - therapeutic use |
2 |
|
glucose intolerance - complications - epidemiology |
2 |
|
goals |
2 |
|
group education |
2 |
|
guideline |
2 |
|
health economics |
2 |
|
health status indicators |
2 |
|
heart |
2 |
|
heart - physiology |
2 |
|
heart atria - metabolism |
2 |
|
heart rate - drug effects |
2 |
|
heart ventricles - drug effects |
2 |
|
heart ventricles - metabolism |
2 |
|
high-density lipoprotein cholesterol |
2 |
|
human |
2 |
|
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage - adverse effects |
2 |
|
hypercholesterolemia - drug therapy |
2 |
|
hypercholesterolemia - drug therapy - economics - prevention & control |
2 |
|
hypercholesterolemia - drug therapy - epidemiology |
2 |
|
hypertension - blood - physiopathology |
2 |
|
hypertension - drug therapy - epidemiology - physiopathology |
2 |
|
hypertension - drug therapy - physiopathology |
2 |
|
hypertension - enzymology - genetics |
2 |
|
hypertension - epidemiology - prevention & control - therapy |
2 |
|
hypertension, renal - physiopathology |
2 |
|
hypertrophy, left ventricular - diagnosis - prevention & control - ultrasonography |
2 |
|
hypolipidemic agents - therapeutic use |
2 |
|
immobilization |
2 |
|
immobilization - physiology |
2 |
|
in situ hybridization |
2 |
|
inappropriate prescribing |
2 |
|
incidence |
2 |
|
infection/inflammation |
2 |
|
inflammation mediators - pharmacology |
2 |
|
interleukin-1 - analysis |
2 |
|
interleukin-1 - metabolism |
2 |
|
interleukin-6 - analysis |
2 |
|
interleukin-6 - genetics - metabolism |
2 |
|
interleukin-6 - metabolism |
2 |
|
interleukins - biosynthesis - blood |
2 |
|
intima-media thickness |
2 |
|
introns |
2 |
|
kidney - blood supply - physiopathology |
2 |
|
kidney - drug effects - metabolism |
2 |
|
kidney - pathology |
2 |
|
left ventricular hypertrophy |
2 |
|
lipid lowering medication |
2 |
|
lipid regulation |
2 |
|
lipopolysaccharides - chemistry - metabolism |
2 |
|
lipopolysaccharides - pharmacology |
2 |
|
lipopolysaccharides - toxicity |
2 |
|
liver - drug effects - metabolism |
2 |
|
liver fat score |
2 |
|
logistic models |
2 |
|
lorcaserin |
2 |
|
lupus erythematosus, systemic - blood |
2 |
|
lupus erythematosus, systemic - blood - immunology - pathology |
2 |
|
lupus nephritis - blood - immunology - pathology |
2 |
|
macrophage migration-inhibitory factors - metabolism |
2 |
|
macrophages - metabolism |
2 |
|
magnetic resonance imaging |
2 |
|
mathematical models |
2 |
|
medical oncology |
2 |
|
mercury |
2 |
|
mesenteric arteries - chemistry |
2 |
|
meta-analysis as topic |
2 |
|
metabolic syndrome x - epidemiology - genetics - metabolism |
2 |
|
methylmercury |
2 |
|
mexican americans - statistics & numerical data |
2 |
|
motion control |
2 |
|
myocardial infarction - blood - diagnosis - drug therapy |
2 |
|
myocardial infarction - economics - psychology - therapy |
2 |
|
myocardial infarction - enzymology - genetics |
2 |
|
myocardial ischemia |
2 |
|
myocardium - chemistry |
2 |
|
national health and nutrition examination survey (nhanes) |
2 |
|
neoplasms - drug therapy - economics |
2 |
|
nice |
2 |
|
nifedipine - therapeutic use |
2 |
|
nitric oxide |
2 |
|
nitric oxide synthase type iii - genetics |
2 |
|
non-alcoholic fatty liver disease score |
2 |
|
nuclease protection assays |
2 |
|
obesity - complications - epidemiology |
2 |
|
orlistat |
2 |
|
outcome and process assessment (health care) - economics |
2 |
|
overweight - complications - epidemiology |
2 |
|
patient compliance |
2 |
|
patient education as topic |
2 |
|
patient education as topic - economics |
2 |
|
peptide |
2 |
|
peptides - analysis - genetics |
2 |
|
peptides - blood - metabolism |
2 |
|
peptides - genetics - metabolism |
2 |
|
peptides - metabolism - physiology |
2 |
|
peptidyl-dipeptidase a - genetics |
2 |
|
pharmacology |
2 |
|
phenotype |
2 |
|
phentermine |
2 |
|
plasma |
2 |
|
point mutation |
2 |
|
point mutation - genetics |
2 |
|
posture |
2 |
|
posture - physiology |
2 |
|
pravastatin - economics - therapeutic use |
2 |
|
prediabetic state - epidemiology |
2 |
|
prescription medications |
2 |
|
priority journal |
2 |
|
protein precursors - genetics |
2 |
|
quality-adjusted life years |
2 |
|
receptors, adrenomedullin - metabolism |
2 |
|
receptors, interleukin-6 - genetics - metabolism |
2 |
|
references (31) view in table layout |
2 |
|
references (35) view in table layout |
2 |
|
regional blood flow - drug effects |
2 |
|
rehabilitation |
2 |
|
renal artery |
2 |
|
renal failure |
2 |
|
renovascular hypertension |
2 |
|
rimonabant |
2 |
|
risk reduction behavior |
2 |
|
rna - analysis - biosynthesis |
2 |
|
rna, messenger - analysis |
2 |
|
rna, messenger - analysis - biosynthesis |
2 |
|
rna, messenger - metabolism |
2 |
|
robustness (control systems) |
2 |
|
sfa |
2 |
|
sibutramine |
2 |
|
signal transduction - drug effects |
2 |
|
simvastatin - administration & dosage - adverse effects |
2 |
|
sodium glucose cotransporter-2 inhibitors |
2 |
|
spleen |
2 |
|
spleen - drug effects - metabolism |
2 |
|
statistics, nonparametric |
2 |
|
stopp/start criteria |
2 |
|
stroke risk |
2 |
|
surgical instruments |
2 |
|
tesofensine |
2 |
|
tgf-β1 |
2 |
|
tolerability |
2 |
|
transforming growth factor beta1 - genetics |
2 |
|
transportation - statistics & numerical data |
2 |
|
travel |
2 |
|
tumor necrosis factor-alpha - analysis |
2 |
|
tumor necrosis factor-alpha - biosynthesis |
2 |
|
tumor necrosis factor-alpha - metabolism |
2 |
|
tunica intima - ultrasonography |
2 |
|
tunica media - ultrasonography |
2 |
|
urotensin |
2 |
|
urotensin ii receptor |
2 |
|
usfa |
2 |
|
vasculature |
2 |
|
vasoactive peptides |
2 |
|
vasoconstriction |
2 |
|
vasodilation |
2 |
|
venous thrombosis |
2 |
|
venous thrombosis - epidemiology |
2 |
|
venous thrombosis - genetics |
2 |
|
ventricles |
2 |
|
weight loss |
2 |
|
world health |
2 |
|
xanthine oxidase inhibitor |
2 |
|
'do not use' list |
1 |
|
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor |
1 |
|
abdominal fat - physiology |
1 |
|
acarbose |
1 |
|
acute coronary syndrome |
1 |
|
acute disease |
1 |
|
acute general hospital |
1 |
|
acute kidney failure |
1 |
|
adipocytokines |
1 |
|
age |
1 |
|
albuminuria - urine |
1 |
|
alcohol drinking |
1 |
|
alcohol drinking - epidemiology |
1 |
|
algorithm |
1 |
|
algorithms |
1 |
|
alisma orientalis |
1 |
|
all cause mortality |
1 |
|
amfepramone |
1 |
|
amiodarone - adverse effects |
1 |
|
amlodipine - adverse effects - therapeutic use |
1 |
|
angina pectoris - drug therapy |
1 |
|
angina, unstable - drug therapy |
1 |
|
angioplasty, balloon, coronary - mortality - rehabilitation |
1 |
|
angiotensin converting enzyme inhibitor |
1 |
|
angiotensin ii |
1 |
|
angiotensin ii type 1 receptor blockers - administration & dosage - therapeutic use |
1 |
|
angiotensin ii type 1 receptor blockers - therapeutic use |
1 |
|
angiotensin receptor antagonists |
1 |
|
angiotensin-converting enzyme inhibitor |
1 |
|
angiotensin-converting enzyme inhibitors |
1 |
|
angiotensin-converting enzyme inhibitors - adverse effects - pharmacology - therapeutic use |
1 |
|
angiotensin-converting enzyme inhibitors - therapeutic use |
1 |
|
angiotensinogen - genetics |
1 |
|
animal |
1 |
|
anoxia - blood |
1 |
|
antacids |
1 |
|
anti-arrhythmia agents - adverse effects |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
anti-obesity agents - adverse effects - pharmacology |
1 |
|
anti-obesity agents - therapeutic use |
1 |
|
anti-obesity drugs |
1 |
|
anticoagulants - administration & dosage |
1 |
|
anticoagulants - adverse effects |
1 |
|
antidiabetic drug |
1 |
|
antihypertensive agents - adverse effects - therapeutic use |
1 |
|
antihypertensive agents - pharmacology |
1 |
|
antilipemic agents - administration & dosage |
1 |
|
antioxidants |
1 |
|
anxiety |
1 |
|
appetite depressants - adverse effects |
1 |
|
arteriosclerosis - drug therapy |
1 |
|
artery occlusion |
1 |
|
arthritis |
1 |
|
aryl hydrocarbon hydroxylases - genetics |
1 |
|
asia |
1 |
|
asia - epidemiology |
1 |
|
aspirin - administration & dosage - adverse effects - therapeutic use |
1 |
|
atrial fibrillation - drug therapy |
1 |
|
atrial natriuretic factor - blood |
1 |
|
atrial natriuretic factor - metabolism - pharmacology |
1 |
|
atrioventricular node - physiopathology |
1 |
|
attitudes |
1 |
|
autoradiography |
1 |
|
bacillus cereus - physiology |
1 |
|
bar-code assisted medication administration (bcma) |
1 |
|
bar-coded patient identification |
1 |
|
bat |
1 |
|
benzimidazoles - administration & dosage - therapeutic use |
1 |
|
bilirubin |
1 |
|
bilirubin - blood |
1 |
|
binding affinity |
1 |
|
binding site |
1 |
|
biomarkers |
1 |
|
biphenyl compounds - pharmacology |
1 |
|
blood glucose |
1 |
|
blood pressure regulation |
1 |
|
blood-vessels -- diseases |
1 |
|
body weights and measures |
1 |
|
bradycardia |
1 |
|
brain ischemia - drug therapy |
1 |
|
brain natriuretic peptide |
1 |
|
burnout |
1 |
|
c-reactive protein - analysis - physiology |
1 |
|
calcitonin gene-related peptide - metabolism - physiology |
1 |
|
calcium channel blocker |
1 |
|
calcium channel blockers |
1 |
|
calcium channel blockers - adverse effects - therapeutic use |
1 |
|
cancer incidence |
1 |
|
captopril - analogs & derivatives - therapeutic use |
1 |
|
carbohydrates |
1 |
|
cardiac output, low - blood - ultrasonography |
1 |
|
cardiac pacing, artificial - adverse effects - methods |
1 |
|
cardiology. |
1 |
|
cardiopulmonary resuscitation |
1 |
|
cardiovascular continuum |
1 |
|
cardiovascular diseases - chemically induced |
1 |
|
cardiovascular diseases - drug therapy - metabolism |
1 |
|
cardiovascular diseases - drug therapy - physiopathology |
1 |
|
cardiovascular diseases - epidemiology - ethnology - metabolism |
1 |
|
cardiovascular diseases - epidemiology - etiology |
1 |
|
cardiovascular diseases - etiology - mortality - prevention & control |
1 |
|
cardiovascular diseases - etiology - physiopathology |
1 |
|
cardiovascular diseases - genetics |
1 |
|
cardiovascular diseases - metabolism |
1 |
|
cardiovascular diseases - physiopathology - prevention & control |
1 |
|
cardiovascular outcome |
1 |
|
cardiovascular physiological phenomena |
1 |
|
cell adhesion molecules - blood - metabolism |
1 |
|
cerebrovascular accident |
1 |
|
child |
1 |
|
children |
1 |
|
china - ethnology |
1 |
|
choroid diseases - drug therapy - pathology |
1 |
|
chromosomes |
1 |
|
chromosomes, human, pair 17 - genetics |
1 |
|
cirrhosis |
1 |
|
clinical trial |
1 |
|
clinical trials -- congresses. |
1 |
|
clinical trials as topic |
1 |
|
computerised prescription order entry |
1 |
|
computerized physician order entry |
1 |
|
coronary disease - drug therapy - mortality - physiopathology |
1 |
|
coronary disease - prevention & control |
1 |
|
coronavirinae |
1 |
|
creatinine - blood - urine |
1 |
|
creatinine - urine |
1 |
|
crizotinib |
1 |
|
cross-over studies |
1 |
|
cushing disease |
1 |
|
cyclobutanes - adverse effects |
1 |
|
cyclobutanes - therapeutic use |
1 |
|
cyclooxygenase inhibitors - administration & dosage - adverse effects - therapeutic use |
1 |
|
cyp2c9 gene |
1 |
|
cytomegalovirus infection |
1 |
|
data interpretation, statistical |
1 |
|
dddr pacing |
1 |
|
decision making |
1 |
|
dexamethasone - therapeutic use |
1 |
|
diabetes complications |
1 |
|
diabetes complications - prevention & control |
1 |
|
diabetes mellitus - epidemiology - ethnology - metabolism |
1 |
|
diabetes mellitus, type 2 - complications - physiopathology |
1 |
|
diabetes mellitus, type 2 - epidemiology - etiology - prevention & control |
1 |
|
diabetic nephropathies - drug therapy |
1 |
|
diabetic nephropathy |
1 |
|
diabeties |
1 |
|
diagnosis, differential |
1 |
|
diastole - physiology |
1 |
|
diastolic dysfunction |
1 |
|
diet -- encyclopedias. |
1 |
|
diet restriction |
1 |
|
diet supplementation |
1 |
|
dihydropyridines |
1 |
|
dihydropyridines - adverse effects - therapeutic use |
1 |
|
dinical trials |
1 |
|
dioscorea opposita |
1 |
|
dipeptidyl peptidase-4 inhibitor |
1 |
|
direct observation |
1 |
|
disease models, animal |
1 |
|
disease outbreaks |
1 |
|
disease-free survival |
1 |
|
dispensing |
1 |
|
dispensing errors |
1 |
|
dna - genetics |
1 |
|
doctor patient relationship |
1 |
|
doppler echocardiography |
1 |
|
dose response |
1 |
|
dose-response |
1 |
|
drug administration |
1 |
|
drug administration errors |
1 |
|
drug interactions that affect blood glucose concentrations |
1 |
|
drug prescriptions - statistics & numerical data |
1 |
|
drug synergism |
1 |
|
drug therapy |
1 |
|
drug use |
1 |
|
drug utilization |
1 |
|
drug utilization review |
1 |
|
drugs that lower blood glucose concentration |
1 |
|
drugs that raise blood glucose concentrations |
1 |
|
duodenal ulcer |
1 |
|
dyslipidemias - blood - drug therapy - ethnology |
1 |
|
editorial |
1 |
|
educational status |
1 |
|
endophthalmitis - drug therapy - pathology |
1 |
|
epidemic |
1 |
|
error-prone abbreviations |
1 |
|
essential hypertension |
1 |
|
ethnic difference |
1 |
|
european continental ancestry group - genetics |
1 |
|
evidence-based medicine |
1 |
|
eye infections, bacterial - drug therapy - pathology |
1 |
|
ezetimibe |
1 |
|
factorial analysis |
1 |
|
false positive reactions |
1 |
|
felodipine |
1 |
|
felodipine - adverse effects - therapeutic use |
1 |
|
fetuin-a |
1 |
|
fibrinogen - analysis |
1 |
|
fibrinolytic agents - therapeutic use |
1 |
|
follow up |
1 |
|
fosinopril |
1 |
|
fructus corni |
1 |
|
functional class |
1 |
|
gamma-glutamyltransferase |
1 |
|
gastric ulcer |
1 |
|
generalized anxiety disorder |
1 |
|
genetic heterogeneity |
1 |
|
glomerular filtration rate |
1 |
|
glomerular filtration rate - drug effects |
1 |
|
glomerulus |
1 |
|
glucagon-like peptide 1 receptor agonist |
1 |
|
glycemic index |
1 |
|
gram-positive bacterial infections - drug therapy - pathology |
1 |
|
gtp-binding proteins - genetics |
1 |
|
half-life |
1 |
|
hazards of general drugs when used in patients with diabetes |
1 |
|
health care surveys |
1 |
|
health insurance |
1 |
|
heart - drug effects - physiology |
1 |
|
heart arrest - therapy |
1 |
|
heart block - physiopathology - therapy |
1 |
|
heart diseases - blood - diagnosis |
1 |
|
heart failure - blood |
1 |
|
heart failure, congestive - blood |
1 |
|
heart protection |
1 |
|
heart ventricles - anatomy & histology - physiopathology |
1 |
|
hematuria - chemically induced |
1 |
|
heme oxygenase |
1 |
|
heme oxygenase-1 - metabolism |
1 |
|
hemostasis |
1 |
|
high blood pressure |
1 |
|
high risk patient |
1 |
|
hla-b,5801 |
1 |
|
hmg-coa reductase inhibitor |
1 |
|
hospitalization - statistics & numerical data |
1 |
|
hospitals, general - statistics & numerical data |
1 |
|
hospitals, university - statistics & numerical data |
1 |
|
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage |
1 |
|
hypercholesterolemia - epidemiology |
1 |
|
hypercholesterolemia - epidemiology - ethnology - metabolism |
1 |
|
hypertension - blood |
1 |
|
hypertension - blood - complications |
1 |
|
hypertension - blood - drug therapy - etiology |
1 |
|
hypertension - blood - epidemiology - genetics - physiopathology |
1 |
|
hypertension - drug therapy - ethnology |
1 |
|
hypertension - drug therapy - mortality - physiopathology |
1 |
|
hypertension - enzymology - genetics - physiopathology |
1 |
|
hypertension - epidemiology - etiology - prevention & control |
1 |
|
hypertension - ethnology - metabolism - physiopathology |
1 |
|
hypertension - etiology - physiopathology |
1 |
|
hypertension -- encyclopedias. |
1 |
|
hypertension. |
1 |
|
hypertrophy, left ventricular - blood - diagnosis |
1 |
|
hypertrophy, left ventricular - chemically induced |
1 |
|
imidazoles - pharmacology |
1 |
|
incretin-modulators |
1 |
|
infections |
1 |
|
injections |
1 |
|
intercellular adhesion molecule-1 - blood |
1 |
|
interleukin-6 - genetics |
1 |
|
interviews as topic |
1 |
|
iridocyclitis - drug therapy - pathology |
1 |
|
ischemic heart disease |
1 |
|
isradipine |
1 |
|
isradipine - adverse effects - therapeutic use |
1 |
|
kidney - drug effects - physiopathology |
1 |
|
kidney failure, chronic - blood |
1 |
|
kidney medulla |
1 |
|
lactones - adverse effects - pharmacology |
1 |
|
letter |
1 |
|
life expectancy |
1 |
|
lifestyle modification |
1 |
|
lipase - antagonists and inhibitors |
1 |
|
lipids - blood |
1 |
|
lipoproteins |
1 |
|
liver - enzymology |
1 |
|
liver cirrhosis - blood |
1 |
|
losartan - administration & dosage - therapeutic use |
1 |
|
lung cancer |
1 |
|
lung diseases, obstructive - blood |
1 |
|
malignant neoplastic disease |
1 |
|
medical order entry systems - statistics & numerical data |
1 |
|
medication errors - statistics & numerical data |
1 |
|
medication incidents |
1 |
|
medication safety in the elderly |
1 |
|
meta analysis |
1 |
|
metabolic pathway |
1 |
|
metabolic syndrome x - complications - epidemiology - prevention & control |
1 |
|
metabolic syndrome x - complications - physiopathology |
1 |
|
metabolic syndrome x - metabolism - physiopathology |
1 |
|
metabolic syndrome x - physiopathology |
1 |
|
metabolic syndrome. |
1 |
|
metformin |
1 |
|
microsatellite |
1 |
|
microsatellite repeats - genetics |
1 |
|
mixed function oxygenases - genetics |
1 |
|
models, cardiovascular |
1 |
|
morbidity |
1 |
|
myocardial infarction - complications - mortality - rehabilitation |
1 |
|
myocardial infarction - drug therapy - mortality - physiopathology |
1 |
|
myopathy |
1 |
|
natriuresis |
1 |
|
natriuretic peptide, brain - metabolism - pharmacology |
1 |
|
natriuretic peptide, c-type - metabolism - pharmacology |
1 |
|
natriuretic pepytides |
1 |
|
non-intercepted medication errors |
1 |
|
nonhuman |
1 |
|
obesity - blood - complications - genetics |
1 |
|
obesity - complications - drug therapy |
1 |
|
obesity - complications - epidemiology - prevention & control |
1 |
|
obesity - complications - physiopathology |
1 |
|
obesity - drug therapy - metabolism |
1 |
|
obesity - epidemiology - therapy |
1 |
|
obesity - physiopathology |
1 |
|
osteoarthritis |
1 |
|
outcome assessment (medical care) -- congresses. |
1 |
|
paeonia suffruticosa |
1 |
|
patient selection |
1 |
|
peptic ulcer |
1 |
|
pericardial fat |
1 |
|
peripheral vascular diseases - blood - epidemiology |
1 |
|
pharmaceutical inspection cooperation scheme |
1 |
|
pharmacogenetics |
1 |
|
pioglitazone |
1 |
|
piperidines - adverse effects - pharmacology |
1 |
|
pitavastatin |
1 |
|
placebos |
1 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects - therapeutic use |
1 |
|
pneumonia |
1 |
|
population |
1 |
|
population science |
1 |
|
poria cocos |
1 |
|
postgraduate education |
1 |
|
potassium - blood |
1 |
|
potassium - urine |
1 |
|
potentially inappropriate medications |
1 |
|
practice guidelines as topic |
1 |
|
pramlintide |
1 |
|
prescribing errors |
1 |
|
prescription |
1 |
|
prescription errors |
1 |
|
prescription omissions |
1 |
|
prescriptions |
1 |
|
promoter regions, genetic |
1 |
|
publication bias |
1 |
|
pulse - drug effects |
1 |
|
quality‐of‐life |
1 |
|
questionnaire |
1 |
|
rabbits |
1 |
|
random allocation |
1 |
|
rat |
1 |
|
rate control |
1 |
|
rats, inbred shr |
1 |
|
receptor binding |
1 |
|
receptors, calcitonin gene-related peptide - metabolism - physiology |
1 |
|
recurrence |
1 |
|
references (30) view in table layout |
1 |
|
references (40) view in table layout |
1 |
|
references (9) view in table layout |
1 |
|
rendu osler weber disease |
1 |
|
renin - genetics |
1 |
|
renin-angiotensin system - drug effects |
1 |
|
research |
1 |
|
rhabdomyolysis |
1 |
|
rheumatoid arthritis |
1 |
|
rhythm control |
1 |
|
risk |
1 |
|
risk reduction |
1 |
|
rosiglitazone |
1 |
|
scad |
1 |
|
severe cutaneous adverse reactions |
1 |
|
shock, septic - physiopathology |
1 |
|
short survey |
1 |
|
signal transduction - physiology |
1 |
|
sinoatrial block - physiopathology - therapy |
1 |
|
snp genotyping |
1 |
|
socio-technical errors |
1 |
|
sodium - blood |
1 |
|
sodium - urine |
1 |
|
sodium chloride, dietary - adverse effects |
1 |
|
sodium–glucose co-transporter 2 inhibitor |
1 |
|
sri lanka |
1 |
|
stand-alone bcma system |
1 |
|
statin |
1 |
|
statistical significance |
1 |
|
stroke - diagnosis - etiology |
1 |
|
stroke - drug therapy |
1 |
|
subclinical atherosclerosis |
1 |
|
survival analysis |
1 |
|
swiss cheese model |
1 |
|
t2d |
1 |
|
technology-related medication errors |
1 |
|
telephone survey |
1 |
|
tetrazoles - administration & dosage - therapeutic use |
1 |
|
tetrazoles - pharmacology |
1 |
|
tetrazoles - therapeutic use |
1 |
|
therapeutics |
1 |
|
thiazide diuretic |
1 |
|
thrombolytic therapy |
1 |
|
thrombosis - drug therapy |
1 |
|
ticagrelor |
1 |
|
ticlopidine - administration & dosage - adverse effects - analogs & derivatives - therapeutic use |
1 |
|
tyrosine kinase inhibitor |
1 |
|
uk prospective diabetes study (ukpds) |
1 |
|
unapproved abbreviations |
1 |
|
united kingdom |
1 |
|
urotensins - blood |
1 |
|
valine - administration & dosage - analogs & derivatives - therapeutic use |
1 |
|
valine - analogs & derivatives - therapeutic use |
1 |
|
vancomycin - therapeutic use |
1 |
|
vascular calcification |
1 |
|
vascular disease |
1 |
|
vascular diseases - epidemiology |
1 |
|
vasculitis - drug therapy - pathology |
1 |
|
vasoactive peptide |
1 |
|
vasodilation - physiology |
1 |
|
vasodilator agents |
1 |
|
ventricular dysfunction, left - blood |
1 |
|
ventricular function - physiology |
1 |
|
ventricular function, left - physiology |
1 |
|
vertebral artery dissection - complications - diagnosis |
1 |
|
visit-to-visit blood pressure variability |
1 |
|
vitamins |
1 |
|
vitreous body - drug effects - microbiology |
1 |
|
vkorc1 gene |
1 |
|
warfarin - administration & dosage |
1 |
|
warfarin - adverse effects |
1 |
|
β-blocker |
1 |
